Recombinant interleukin-2 and recombinant interferon α immunotherapy cardiovascular toxicity

This publication has 26 references indexed in Scilit:

• Pathologic findings associated with interleukin-2—Based immunotherapy for cancer: A postmortem study of 19 patients
  Human Pathology, 1990
• Complete heart block due to interleukin-2 therapy
  American Heart Journal, 1990
• Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer
  Intensive Care Medicine, 1990
• Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
  Annals of Surgery, 1989
• Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
  Journal of Clinical Oncology, 1989
• Interleukin-2 Administration Causes Reversible Hemodynamic Changes and Left Ventricular Dysfunction Similar to Those Seen in Septic Shock
  Chest, 1988
• Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells
  Annals of Internal Medicine, 1988
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Hemodynamic studies and results of therapy in 50 patients with bacteremic shock
  The American Journal of Medicine, 1973